Key facts
- Brevium’s last known valuation is $40.0M (Sep 2024).
- It has raised $4.0M across 3 recorded rounds; the latest was Seed Round ($1.0M) in Jul 2025.
- Notable investors include Frazier VC.
- Brevium has filed 3 Form Ds with the SEC since 2023, most recently Aug 2025 ($1.0M sold to 1 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Brevium
Funding rounds
3 roundsAbout Brevium
Developer of a patient reactivation tool intended to optimize schedules and achieve exceptional practice growth. The company's data-driven system interfaces with practice management systems to improve patient care and fill schedules with high-priority patients and specialization in patient follow-up to find and reactivate the thousands of patients who have stopped responding to the reminders and focuses on the patient appointment lifecycle, enabling healthcare providers to return patients lost to medical practices and for the care they need.
- Sector
- Healthcare
- HQ
- American Fork, UT, United States
- Founded
- 2004
- Employees
- 79
- Website
- brevium.com/
- Ownership
- Privately Held (backing)
Brevium doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Brevium shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Brevium in its N-PORT filings yet. We sweep new filings monthly.